Skip to main content

Eli Lilly to invest $1.8 billion to expand manufacturing for weight loss, diabetes and Alzheimer's drugs

Demand for Eli Lilly's Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily to increase production.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.